{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:23:57Z","timestamp":1787865837037,"version":"build-2784847793"},"reference-count":10,"publisher":"CSIRO Publishing","issue":"2","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":499,"URL":"https:\/\/doi.org\/10.1071\/journalslicense"}],"funder":[{"name":"CureKids New Zealand","award":["7012"],"award-info":[{"award-number":["7012"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,11]]},"abstract":"<jats:p>Syphilis is an important global health threat and little has changed in its treatment since the mid-20th century. For late-latent or syphilis infection of unknown duration, the standard treatment of multiple intramuscular injections of benzathine penicillin G (BPG) are associated with significant pain and distress to clients and caregivers, negatively impacting on treatment completion. Based on pharmacokinetic modelling from a Phase I study of subcutaneous infusion of high dose BPG (SCIP), we present its feasibility, safety and tolerability for treatment of syphilis in a single infusion. SCIP leads to more sustained penicillin concentrations above the desired target with less reported pain and reduced clinic visits.<\/jats:p>","DOI":"10.1071\/sh24003","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T18:12:32Z","timestamp":1711390352000},"source":"Crossref","is-referenced-by-count":5,"title":["Could late-latent syphilis be treated with a single subcutaneous infusion of long-acting penicillin?"],"prefix":"10.1071","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5233-4438","authenticated-orcid":true,"given":"Thel K.","family":"Hla","sequence":"first","affiliation":[{"name":"AWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia."},{"name":"BMedical School, University of Western Australia, Perth, WA, Australia."},{"name":"CDepartment of Infectious Diseases, Fiona Stanley Hospital, Perth, WA, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Salman","sequence":"additional","affiliation":[{"name":"AWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia."},{"name":"BMedical School, University of Western Australia, Perth, WA, Australia."},{"name":"DClinical Pharmacology and Toxicology Unit, PathWest, WA, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kado","sequence":"additional","affiliation":[{"name":"AWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia."},{"name":"BMedical School, University of Western Australia, Perth, WA, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brioni R.","family":"Moore","sequence":"additional","affiliation":[{"name":"AWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia."},{"name":"BMedical School, University of Western Australia, Perth, WA, Australia."},{"name":"ECurtin Medical School, Curtin University, Perth, WA, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurens","family":"Manning","sequence":"additional","affiliation":[{"name":"AWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia."},{"name":"BMedical School, University of Western Australia, Perth, WA, Australia."},{"name":"CDepartment of Infectious Diseases, Fiona Stanley Hospital, Perth, WA, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"67","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"issue":"8","key":"2025102615343627800_R1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.2471\/BLT.18.228486","article-title":"Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016.","volume":"97","author":"Rowley","year":"2019","journal-title":"Bull World Health Organ"},{"key":"2025102615343627800_R2"},{"key":"2025102615343627800_R3"},{"issue":"1","key":"2025102615343627800_R4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/00005792-195602000-00002","article-title":"Inoculation syphilis in human volunteers.","volume":"35","author":"Magnuson","year":"1956","journal-title":"Medicine"},{"issue":"5","key":"2025102615343627800_R5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/OLQ.0000000000001775","article-title":"Treatment completion with three-dose series of benzathine penicillin among people diagnosed with late latent and unknown duration syphilis, Maricopa County, Arizona.","volume":"50","author":"Mangone","year":"2023","journal-title":"Sex Transm Dis"},{"key":"2025102615343627800_R6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/ajo.13424","article-title":"Addressing the crisis of congenital syphilis: key findings from an evaluation of the management of syphilis in pregnancy and the newborn in South-East Queensland.","volume":"62","author":"Wu","year":"2022","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"2 Pt 2","key":"2025102615343627800_R7","first-page":"109","article-title":"Biopharmacology of syphilotherapy.","volume":"3","author":"Rein","year":"1976","journal-title":"J Am Vener Dis Assoc"},{"issue":"4","key":"2025102615343627800_R8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/00007435-198110000-00005","article-title":"The introduction of penicillin for the treatment of syphilis.","volume":"8","author":"Kampmeier","year":"1981","journal-title":"Sex Transm Dis"},{"key":"2025102615343627800_R9","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00962-23","article-title":"Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study.","volume":"67","author":"Kado","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2025102615343627800_R10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285037","article-title":"Qualitative assessment of healthy volunteer experience receiving subcutaneous infusions of high-dose benzathine penicillin G (SCIP) provides insights into design of late phase clinical studies.","volume":"18","author":"Enkel","year":"2023","journal-title":"PLoS ONE"}],"container-title":["Sexual Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH24003\/587962\/sh24003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH24003\/587962\/sh24003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:34:43Z","timestamp":1761507283000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/sh\/article\/21\/2\/SH24003\/82241\/Could-late-latent-syphilis-be-treated-with-a"}},"subtitle":[],"editor":[{"given":"Michael","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4,11]]}},"URL":"https:\/\/doi.org\/10.1071\/sh24003","relation":{},"ISSN":["1448-5028","1449-8987"],"issn-type":[{"value":"1448-5028","type":"print"},{"value":"1449-8987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"article-number":"SH24003"}}